Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a

Moderna, Inc. (MRNA) Net margin

Alert me on Net margin

Moderna, Inc.'s net margin over the twelve months to 30 June 2026 was −141.4%, up 3.7 percentage points from fiscal 2025 (−145.2%). Over the past ten years it has ranged from −856.7% (fiscal 2019) to 66.1% (fiscal 2021); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −145.2% (35.12)
FY2024 −110.0% (41.20)
FY2023 −68.8% (112.25)
FY2022 43.4% (22.65)
FY2021 66.1% 159.09
FY2020 −93.0% 763.64
FY2019 −856.7% (559.15)
FY2018 −297.5% (166.42)
FY2017 −131.1% 81.37
FY2016 −212.5% —

Quarterly newest first

Period Net margin Change (points)
Jun 2026 −539.3% (194.07)
Mar 2026 −345.2% (223.41)
Dec 2025 −121.8% (102.14)
Sep 2025 −19.7% 561.30
30 more quarters

Against its own ten years

Low −856.7% High 66.1%
Ten-year median −120.6%
Current reading's percentile 35

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on MRNA